Nanoform Finland Oyj (FRA:4YL)
Germany · Delayed Price · Currency is EUR | Market Cap | 86.44M +8.3% |
| Revenue (ttm) | 5.42M +37.7% |
| Net Income | -15.97M |
| EPS | -0.19 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.9870 |
| Previous Close | 0.9750 |
| Day's Range | 0.9870 - 0.9870 |
| 52-Week Range | 0.4135 - 1.2680 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 20, 2026 |
About Nanoform Finland Oyj
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) nanoparticles directly from solution; biological nanoforming technology; and dosage forms of Nanoparticles. It also offers STARMAP, an AI platform predic... [Read more]
Financial Performance
In 2025, Nanoform Finland Oyj's revenue was 5.02 million, an increase of 37.10% compared to the previous year's 3.66 million. Losses were -17.90 million, -23.60% less than in 2024.
Financial StatementsNews
Nanoform Finland Oyj Earnings Call Transcript: Q1 2026
Record Q1 revenue and gross margin achieved, with operating costs down 31% year-over-year. Signed first exclusivity deal for biologics, validating technology and attracting strong industry interest. On track for 2026 cash burn target and 2030 growth goals.
Nanoform Finland Oyj Quarterly report: Q1 2026
Nanoform Finland Oyj has published its Q1 2026 quarterly earnings report on May 19, 2026.
Nanoform Finland Oyj Slides: Q1 2026
Nanoform Finland Oyj has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 19, 2026.
Nanoform Finland Oyj: Nanoform Q1 2026 report - Record first quarter revenue, income and gross margin, first exclusivity deal signed around our Biologics technology
Nanoform Finland Plc | Company Release | May 19, 2026 at 08:10:00 EEST Record first quarter revenue, income and gross margin. Revenue grew by 45%, gross margin reached 94% and operating costs fell ...
Nanoform Finland Oyj: Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery
Nanoform Finland Plc | Inside Information | May 12, 2026 at 08:00:00 EEST Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it ...
Nanoform Finland Oyj: The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees
Nanoform Finland Plc | Company Release | March 02, 2026 at 08:10:00 EET Helsinki, Finland - The Annual General Meeting of Nanoform Finland Plc ("Nanoform") has on 15 April 2025 authorized the compa...
Nanoform Finland Oyj Earnings Call Transcript: Q4 2025
Record revenue and EBITDA growth in 2025, driven by new IP, commercial deals, and expansion in Asia. Cash burn is targeted below €10M for 2026, with a strong cash position and several milestone opportunities ahead. Subcutaneous biologics delivery and GMP project share are key growth drivers.
Nanoform Finland Oyj Annual report: Q4 2025
Nanoform Finland Oyj has published its Q4 2025 annual report on February 26, 2026.
Nanoform Finland Oyj Quarterly report: Q4 2025
Nanoform Finland Oyj has published its Q4 2025 quarterly earnings report on February 26, 2026.
Nanoform Finland Oyj Slides: Q4 2025
Nanoform Finland Oyj has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.
Nanoform Finland Oyj: Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe
Nanoform Finland Plc | Company Release | February 26, 2026 at 08:10:00 EET Product kernel strategy continues to gain traction. Nanoenzalutamide: pivotal human fed and fasted study concluded, three ...
Nanoform Finland Oyj: Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 2030
Nanoform Finland Plc | Inside Information | January 07, 2026 at 08:05:00 EET Helsinki, Finland - Nanoform Finland Plc ("Nanoform") starts change negotiations in accordance with the Act on Cooperati...
Nanoform Finland Oyj: Inside information: Nanoform announces new midterm business targets for 2030
Nanoform Finland Plc | Inside Information | December 16, 2025 at 07:00:00 EET Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced new ...
Nanoform Finland Oyj Slides: FY 2025
Nanoform Finland Oyj has posted slides in relation to its FY 2025 quarterly earnings report, which was published on December 16, 2025.
Nanoform Finland Oyj Earnings Call Transcript: Q3 2025
Secured a commercial GMP manufacturing license, expanded product pipeline, and improved cash burn rate to EUR 3.9 million in Q3 2025. Strong cash position and new partnerships support growth, with targets for 2026 cash burn below EUR 10 million.
Nanoform Finland Oyj Quarterly report: Q3 2025
Nanoform Finland Oyj has published its Q3 2025 quarterly earnings report on November 12, 2025.
Nanoform Finland Oyj Slides: Q3 2025
Nanoform Finland Oyj has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 12, 2025.
Nanoform Finland Oyj Earnings Call Transcript: Q2 2025
Q2 2025 saw 23% revenue growth, improved cash flow, and a 98% gross margin, with strong progress in both small molecule and biologics platforms. Key milestones include the first license agreement for nanoenzalutamide, ongoing pivotal studies, and expanded global partnerships.
Nanoform Finland Oyj Quarterly report: Q2 2025
Nanoform Finland Oyj has published its Q2 2025 quarterly earnings report on August 21, 2025.
Nanoform Finland Oyj Slides: Q2 2025
Nanoform Finland Oyj has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 21, 2025.